MXPA03010321A - Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. - Google Patents

Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Info

Publication number
MXPA03010321A
MXPA03010321A MXPA03010321A MXPA03010321A MXPA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A MX PA03010321 A MXPA03010321 A MX PA03010321A
Authority
MX
Mexico
Prior art keywords
receptor
lower alkyl
neurikinin
undecan
diaza
Prior art date
Application number
MXPA03010321A
Other languages
English (en)
Inventor
Cai Hai-Ying
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03010321A publication Critical patent/MXPA03010321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a compuestos de la formula General (ver formula) en la cual: (R1)n es independientemente entre si, halogeno alquilo inferior o alcoxi inferior; R2 es hidrogeno, alquilo inferior, halogeno-alquilo inferior, - (CH2)m-OH, - (CH2)~-NR2~, - (CH2)m0-alquilo inferior, - (CH2)m-C (O) -NR2, O es - (CH2)m ,-heteroarilo de seis miembros, opcionalmente substituido por uno o mas alcoxi inferior, -(CH2)m-heterociclilo no aromatico de 5 o 6 miembros, opcionalmente substituido por hidroxi o alquilo inferior, R es hidrogeno o alquilo inferior y puede ser igual o diferente en caso de R2; n es 0,1 o 2 m es 0, 1, 2, 3 o 4; y a sales de adicion acidas farmaceuticamente aceptables de los mismos. Estos compuestos presentan una buena afinidad por el receptor de NK-1, y por lo tanto, son adecuados para el tratamiento de enfermedades relacionadas con dicho receptor.
MXPA03010321A 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina. MXPA03010321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (1)

Publication Number Publication Date
MXPA03010321A true MXPA03010321A (es) 2004-02-17

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010321A MXPA03010321A (es) 2001-05-14 2002-05-06 Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.

Country Status (17)

Country Link
US (1) US6599900B2 (es)
EP (1) EP1390372B1 (es)
JP (1) JP4056887B2 (es)
KR (1) KR100618063B1 (es)
CN (1) CN1264847C (es)
AR (1) AR033631A1 (es)
AT (1) ATE401333T1 (es)
AU (1) AU2002342238B2 (es)
BR (1) BR0209604A (es)
CA (1) CA2447329C (es)
DE (1) DE60227657D1 (es)
DK (1) DK1390372T3 (es)
ES (1) ES2310206T3 (es)
MX (1) MXPA03010321A (es)
PT (1) PT1390372E (es)
WO (1) WO2002092604A1 (es)
ZA (1) ZA200308535B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100497346C (zh) * 2004-02-10 2009-06-10 弗·哈夫曼-拉罗切有限公司 趋化因子ccr5受体调控剂
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2598530C (en) 2005-03-03 2014-12-16 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
NZ556628A (en) 2005-03-08 2009-09-25 Janssen Pharmaceutica Nv Diaza-spiro-[4.4]-nonane derivatives as neurokinin (NK1) antagonists
US7470684B2 (en) 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
CN101646679A (zh) 2007-03-29 2010-02-10 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
EA035823B1 (ru) 2015-07-31 2020-08-17 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
KR20190104405A (ko) 2017-01-20 2019-09-09 화이자 인코포레이티드 Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
JP2020506903A (ja) 2017-01-23 2020-03-05 ファイザー・インク Ｍａｇｌ阻害薬としての複素環式スピロ化合物
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE274499T1 (de) * 1995-09-29 2004-09-15 Lilly Co Eli Spiro verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation

Also Published As

Publication number Publication date
US6599900B2 (en) 2003-07-29
CN1264847C (zh) 2006-07-19
WO2002092604A1 (en) 2002-11-21
PT1390372E (pt) 2008-08-25
AR033631A1 (es) 2003-12-26
JP4056887B2 (ja) 2008-03-05
JP2004534758A (ja) 2004-11-18
AU2002342238B2 (en) 2007-01-25
EP1390372A1 (en) 2004-02-25
EP1390372B1 (en) 2008-07-16
KR100618063B1 (ko) 2006-08-30
CN1507449A (zh) 2004-06-23
US20030004163A1 (en) 2003-01-02
CA2447329C (en) 2009-07-28
ATE401333T1 (de) 2008-08-15
KR20030094405A (ko) 2003-12-11
ZA200308535B (en) 2005-01-31
DK1390372T3 (da) 2008-09-15
CA2447329A1 (en) 2002-11-21
ES2310206T3 (es) 2009-01-01
BR0209604A (pt) 2004-03-23
DE60227657D1 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
MY147451A (en) 4-phenyl-pyridine derivatives and their use as nk-1 receptor antagonists
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
IL184687A0 (en) Pharmaceutical compositions containing 1,2-dihydropyridin-2-one derivatives
HK1070649A1 (en) Quinoline derivative having azolyl group and quinazoline derivative
MXPA03010321A (es) Derivados de 1-oxa-3,9-diaza-spiro-5,5-undecan-2-onas y su uso como antagonista del receptor de neurocinina.
DE69120100D1 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
AU2002213421A1 (en) Condensed pyridoindole derivatives
JO2321B1 (en) 4-phenyl-pyridine derivatives
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
ATE154021T1 (de) N-cyclohexyl benzamide derivate, ihre herstellungen und therapeutischen anwendungen
HK1054692A1 (en) Composition containing an angiotensin ii receptor antagonist and a diuretic and its use for the treatment of hypertension
DE60208178D1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
AU1367497A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of prostatic carcinoma
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
YU86603A (sh) Novi derivati piperidinkarboksamida, postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
AU2001261707A1 (en) Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives
CA2346896A1 (en) 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme
CA2192596A1 (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety
ZA908309B (en) Dibenzodioxazecine and dibenzodioxaazacycloundecine derivatives

Legal Events

Date Code Title Description
FG Grant or registration